Journals / Göztepe Tıp Dergisi / 2007 / Cilt: 22 - Sayı: 4

Our one year results of photodynamic laser for choroidal neovascularisation

Fotodinamik lazer tedavisinde bir yıllık sonuçlarımız

Pages
128–132
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

TheVA logMAR scores in the non-AMD group were significantly lower than the scores of the AMD group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: To present our one year results of Photodynamic laser treatment for Choroidal neovascularisationMaterial and Methods: We included the patients treated with photodynamic laser between the dates April 2005 and September 2006.
📊
Key Findings & Data:The results were compared between the two groups.Results: The VA in the AMD group was measured as 0.94±0.36 logMAR units before, and 0.95±0.37 after the photodynamic laser treatment.
💡
Conclusion & Impact:TheVA logMAR scores in the non-AMD group were significantly lower than the scores of the AMD group (p
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: To present our one year results of Photodynamic laser treatment for Choroidal neovascularisationMaterial and Methods: We included the patients treated with photodynamic laser between the dates April 2005 and September 2006. The patients were devided in two groups-choroidal neovascularization due to age-related macula degeneration group and the other group included patients with idiopathic CNV and choroidal neovascularisation due to pathologic myopia. The visual acuities (VA) measured with ETDRS chart were converted to the corresponding logMAR acuities. Fundus Fluorescein Angiography (FFA) and Optic Coherence Tomography (OCT) scans were taken before the treatment and during the follow up. The results were compared between the two groups.Results: The VA in the AMD group was measured as 0.94±0.36 logMAR units before, and 0.95±0.37 after the photodynamic laser treatment. In the non-AMD group the VA logMAR score was 1.01±0.34 before, and 0.55±0.44 after the treatment. TheVA logMAR scores in the non-AMD group were significantly lower than the scores of the AMD group (p

Özet

Amaç: Fotodinamik lazer tedavisinde bir yıllık sonuçlarımızı sunmak.Materyal ve metod: Nisan 2005- Eylül 2006 tarihleri arasında kliniğimizde fotodinamik lazer tedavisi uygulanmış hastalar çalışmaya dahil edildi. Olgular yaşa bağlı maküla dejenerasyonu (YBMD) grubu ve yaşa bağlı maküla dejenerasyonu dışı (YBMDD) grubu olarak iki gruba ayrıldı Hastaların, ETDRS eşeli ile değerlendirilen görme keskinliklerinin logMAR eşdeğerleri hesaplandı. Uygulama öncesi ve takiplerde tüm hastalara Fundus Floresein Anjiyografi (FA) ve Optik koherens tomografi (OCT) uygulandı. Elde edilen sonuçlar iki grup arasında karşılaştırıldı. Bulgular: YBMD grubunda uygulama öncesi 0.94±0.36 olan görme keskinliği logMAR (GKlogMAR) değeri uygulama sonrası 0.95±0.37 olarak saptandı. YBMDD grubunda ise uygulama öncesi GKlogMAR 1.01±0.34, sonrasında ise 0.55±0.44 olarak hesaplandı. Uygulama sonrası GKlogMAR değerleri YBMDD grubunda YBMD grubuna göre ileri derecede anlamlı düzeyde düşük olarak saptandı (p

🔖

Cite This Article

SÖNMEZ, A., ACAR, H., AKÇAKAYA, A. A., ERBİL, H. H., YAYLALAI, A. S. (2022). Our one year results of photodynamic laser for choroidal neovascularisation. Göztepe Tıp Dergisi, Cilt: 22 - Sayı: 4, 128–132. https://ajindex.com/articles/526291

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Daniell MD, Hill JS: A history of photodynamic therapy. Aust N Z J Surg 61:340-348, 1991
  2. Schmidt-Erfurth U, Hasan T, Gragoudas E, et al: Vasculer targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 101:1953-1961, 1994
  3. Wachtlin J, Heimann H, Behme T, et al: Long term results after photodynamic therapy with verteporfirin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefes Arch Clin Exp Ophthalmol 241:899-906, 2003
  4. Ergun E, Heinzl H, Stur M: Prognostic factors influencing visual outcome of photodynamic therapy for choroidal neovascularizations in pathologic myopia. Am J Ophthalmol 134:62-68, 2002
  5. Spaide RF, Martin ML, Slakter J, et al: Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfirin. Am J Ophthalmol 134:62-68, 2002
  6. Treatment of Age-related macular degeneration with photodynamic therapy (TAP) and Verteporfirin in photodynamic therapy study groups: Effect of lesion size visual acuity change with and without Verteporfirin therapy for choroidal neovascularization secondary to Age-related macular degeneration: TAP and V‹P report No.1. Am J Ophthalmol 136:407-418, 2003
  7. Alfaro DV, Liggett PE, Mieller WF, et al: Age-related macular degeneration: Classification of age-related macular dageneration. Lippincott Williams&Wilkins. Philadelphia 2006, p:48
  8. Treatment of Age-related macular degeneration with photodynamic therapy(TAP) study group: Photodynamic therapy of subfoveal choroidal neovascularization in Age-related macular degeneration with verteporfirin. One-year results of 2 randomized clinical trials-TAP Report 1. Arch Ophthalmol 117:1329-1345, 1999
  9. Verteporfirin in photodynamic therapy study group: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic miyopia with verteporfirin. 1-year results of a randomized clinical trial-VIP Report No 1. Am J Ophthalmol 108:841-852, 2001
  10. Yetik H, Müftüoğlu G, Akar S, Aras C, Özkan Ş: Oküler fotodinamik tedavide 24 aylık sonuçlarımız. Ret-Vit 13:173-178, 2005.